NUTROPIN AQ NUSPIN
LOE ApproachingBLAINJECTIONINJECTABLE
Approved
Dec 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NUTROPIN AQ NUSPIN is a recombinant human growth hormone (somatropin) administered by injection for growth hormone deficiency and related growth disorders. It is a biologic therapeutic that replaces or supplements endogenous growth hormone to promote normal growth and development in pediatric and adult patients.
$6MPart D
LOE ApproachingWith $6M in Part D spending and approaching loss of exclusivity, this product is in a defensive phase with potential for team restructuring and transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NUTROPIN AQ NUSPIN offers experience in mature biologic portfolio management, competitive dynamics, and LOE transition strategies within a specialized endocrinology space. Career growth depends on strategic repositioning and cross-functional collaboration to defend market share against biosimilar and generic competition.
Brand ManagerMedical Science Liaison
Worked on NUTROPIN AQ NUSPIN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.